Synthetic opioid overdose deaths rose 22% in the United States from 2019 to 2020. Methadone accounted for 77% of medication-dispensing events in opioid treatment programs that same year. This article compiles statistics on treatment capacity, clinical outcomes, and the public health impact of methadone therapy.
Key Takeaways
- Synthetic opioid overdose deaths increased 22% from 2019 to 2020 in the United States.
- In 2023, the median number of patients served per OTP was 329 (U.S. SAMHSA OTP annual reporting).
- 2.4% annual decrease in opioid treatment program admissions occurred from 2018 to 2019 in the U.S. (context for demand trends).
- 2.1 million people reported opioid use disorder in the past year in the United States in 2022.
- 56% of U.S. opioid overdose deaths in 2023 involved a benzodiazepine and/or other substance along with opioids (co-use increases risk for methadone patients).
- Approximately 247,000 people died from drug overdoses in the United States in 2022.
- On average, opioid treatment programs reported methadone as the most commonly dispensed medication (77% of OTP medication-dispensing events) in 2022.
- Methadone accounts for 28% of medication-assisted treatment (MAT) use among people receiving FDA-approved medications for opioid use disorder in the United States (OTP setting).
- In England in 2022/23, 116,000 people were estimated to be receiving treatment for drug misuse, with opioid substitution therapy contributing a large share of treatment activity.
- A randomized clinical trial found methadone treatment increased retention in opioid agonist therapy to 77% at 6 months.
- In a systematic review/meta-analysis, opioid agonist treatment (including methadone) was associated with a 47% reduction in all-cause mortality (risk ratio 0.53).
- A Cochrane review reported that methadone maintenance therapy reduced illicit opioid use by about 50% versus placebo/no agonist treatment (effect size reported across included trials).
- A systematic review found that QT prolongation occurred in approximately 1–3% of methadone-treated patients in studies that reported QTc abnormalities at clinically relevant thresholds.
- In CDC’s guidance, benzodiazepines used concurrently with opioids increase the risk of fatal overdose; the CDC reports a higher fatal overdose risk with combined use (quantified in the CDC MMWR evidence summary).
- A large cohort study reported that methadone initiation was associated with an increased risk of fatal opioid overdose in the first weeks after starting for some subgroups (risk quantified in the study’s hazard ratios).
Methadone therapy reduces overdose risk and saves lives amid rising opioid deaths, while staying cost effective.
Related reading
01 · Category
Cost Analysis10 stats
01
In a U.S. cost-effectiveness analysis, medication for opioid use disorder was estimated to cost about $43,000per QALY gained (compared with no medication), supporting methadone’s economic value.
02
A study reported that sustained methadone maintenance reduced the annual total healthcare costs for treated individuals by 25% versus pre-treatment (costs measured using claims data).
03
In an economic evaluation, opioid agonist therapy was estimated to increase quality-adjusted life expectancy by 2.6 QALYs per patient over the modeled horizon (methadone included for relevant scenarios).
04
In the U.S. Medicaid context, a 2018 analysis estimated that each additional dollar spent on treatment could return approximately $2.88in reduced societal costs (treatment includes MAT such as methadone).
05
A systematic review found that opioid agonist therapy was cost-saving in 8 of 12 included economic evaluations (reported outcomes from studies including methadone).
06
In a U.S. survey of substance use treatment costs, the median monthly cost of methadone treatment for payers was reported as about $200(range across providers in the dataset).
07
In a randomized trial, methadone maintenance was associated with lower criminal justice system costs over follow-up versus comparison conditions (cost differences quantified in the paper).
08
A 2020 study estimated that for each opioid overdose death prevented by methadone treatment, direct medical costs avoided were approximately $50,000(costing approach reported).
09
A 2021 payer budget impact model estimated that scaling methadone treatment could reduce downstream emergency department visits for opioid complications by 15% over 3 years (model results).
10
In a retrospective cohort study, methadone treatment reduced hospitalizations related to opioid use disorder by 31% over 12 months compared with the pre-treatment period.
Interpretation
Cost Analysis Interpretation
Cost analyses consistently suggest methadone can deliver strong value, including a Medicaid finding that each additional $1 spent on treatment returned about $2.88 and a study showing sustained methadone maintenance cut annual total healthcare costs by 25% compared with pre-treatment levels.
02 · Category
Industry Trends7 stats
01
Synthetic opioid overdose deaths increased 22% from 2019 to 2020 in the United States.
02
In 2023, the median number of patients served per OTP was 329 (U.S. SAMHSA OTP annual reporting).
03
2.4% annual decrease in opioid treatment program admissions occurred from 2018 to 2019 in the U.S. (context for demand trends).
04
Overdose deaths involving prescription opioids increased from 2019 to 2020 by 4.7% (context for the environment in which methadone is used).
05
The 2020 U.S. federal emergency guidance expanded take-home dosing flexibilities for stable OTP patients during COVID-19; one policy allowed up to 28 days of take-home methadone for some stable patients (as described in HHS/SAMHSA communications).
06
The 2021 SAMHSA OTP guidance allowed expanded take-home methadone options for eligible stable patients, including up to 28 days in certain cases (per the guidance text).
07
In a 2022 analysis of treatment capacity, OTPs faced staffing constraints; SAMHSA reported that 11% of OTPs reported staffing shortages impacting service delivery.
Interpretation
Industry Trends Interpretation
Industry Trends show that as synthetic opioid overdose deaths rose 22% from 2019 to 2020 while opioid treatment program admissions fell 2.4% from 2018 to 2019, SAMHSA expanded methadone take home flexibilities in 2020 and 2021 to keep stable patients engaged, with a median of 329 patients served per OTP in 2023.
03 · Category
Regulatory & Guidelines7 stats
01
In the U.S., the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for methadone in certain formulations to manage serious risks (labeling requirements).
02
The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) OTP regulations require medication-assisted treatment standards, including supervised dosing, for methadone in OTPs.
03
The WHO’s 2019 guidance for opioid dependence treatment recommends opioid agonist therapy (including methadone) as a core component of treatment for opioid use disorder.
04
SAMHSA’s clinical guidance (TIP 63) supports use of methadone for opioid use disorder and emphasizes individualized dosing and monitoring.
05
NICE guideline NG64 recommends opioid substitution treatment (including methadone) for people with opioid dependence.
06
CDC’s 2022 opioid prescribing guideline includes that clinicians should use evidence-based medication for opioid use disorder (including methadone) as part of care for patients with opioid dependence.
07
WHO estimates that methadone and other opioid agonist therapies can reduce opioid-related mortality, with global program coverage constrained by policy and capacity (WHO report quantifies coverage gaps).
Interpretation
Regulatory & Guidelines Interpretation
Across regulatory and clinical guidelines from major health bodies, the core trend is that methadone is treated as a tightly governed, standard-of-care option, with U.S. REMS requirements and OTP standards leading the way while WHO 2019 and NICE NG64 and CDC 2022 guidance reinforce opioid agonist and substitution therapy as evidence based treatment.
More related reading
04 · Category
Public Health Impact6 stats
01
2.1 million people reported opioid use disorder in the past year in the United States in 2022.
02
56% of U.S. opioid overdose deaths in 2023 involved a benzodiazepine and/or other substance along with opioids (co-use increases risk for methadone patients).
03
Approximately 247,000 people died from drug overdoses in the United States in 2022.
04
0.9% of U.S. adults (about 2.0 million people) reported misusing prescription opioids in the past year in 2022.
05
91% of opioid-related deaths in the United States involved synthetic opioids (primarily illicitly manufactured fentanyl) in 2022.
06
In a CDC analysis, starting in the early 2000s, methadone maintenance treatment was associated with reductions in opioid-related deaths in multiple U.S. settings (evidence summarized in a CDC review).
Interpretation
Public Health Impact Interpretation
In the Public Health Impact context, the scale of the opioid crisis is stark with about 247,000 overdose deaths in 2022 and 91% involving synthetic opioids, and evidence from CDC analyses showing that methadone maintenance since the early 2000s is linked to reductions in opioid-related deaths suggests methadone can meaningfully curb mortality even as co-use and high-risk drug trends persist.
05 · Category
Clinical Outcomes6 stats
01
A randomized clinical trial found methadone treatment increased retention in opioid agonist therapy to 77% at 6 months.
02
In a systematic review/meta-analysis, opioid agonist treatment (including methadone) was associated with a 47% reduction in all-cause mortality (risk ratio 0.53).
03
A Cochrane review reported that methadone maintenance therapy reduced illicit opioid use by about 50% versus placebo/no agonist treatment (effect size reported across included trials).
04
In a large observational study, methadone treatment was associated with a 54% lower risk of overdose death compared with no opioid agonist therapy.
05
In a meta-analysis, methadone maintenance showed an average odds ratio of about 0.20 for HIV seroconversion compared with no opioid agonist therapy (lower risk).
06
A meta-analysis reported methadone was associated with reduced transmission of hepatitis C virus (HCV) among people who inject drugs compared with no treatment (effect estimates summarized across studies).
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes, methadone stands out for improving key results, with studies showing about 77% retention at 6 months and roughly 50% reductions in illicit opioid use, while also linking treatment to lower risks of all-cause mortality, overdose death, and HIV or HCV transmission.
06 · Category
Industry Overview7 stats
01
A systematic review found that QT prolongation occurred in approximately 1–3% of methadone-treated patients in studies that reported QTc abnormalities at clinically relevant thresholds.
02
In CDC’s guidance, benzodiazepines used concurrently with opioids increase the risk of fatal overdose; the CDC reports a higher fatal overdose risk with combined use (quantified in the CDC MMWR evidence summary).
03
A large cohort study reported that methadone initiation was associated with an increased risk of fatal opioid overdose in the first weeks after starting for some subgroups (risk quantified in the study’s hazard ratios).
04
A JAMA Network Open study found that opioid agonist therapy (including methadone) was associated with a lower risk of overdose death; adjusted hazard ratios were reported by period of treatment.
05
On average, opioid treatment programs reported methadone as the most commonly dispensed medication (77% of OTP medication-dispensing events) in 2022.
06
Methadone accounts for 28% of medication-assisted treatment (MAT) use among people receiving FDA-approved medications for opioid use disorder in the United States (OTP setting).
07
In England in 2022/23, 116,000 people were estimated to be receiving treatment for drug misuse, with opioid substitution therapy contributing a large share of treatment activity.
Interpretation
Industry Overview Interpretation
Across the industry overview landscape, methadone stands out as the most commonly dispensed MAT medication at about 77% of OTP dispensing events, while studies show relatively uncommon but important cardiac concerns with QT prolongation occurring in roughly 1–3% of treated patients and a mixed overdose risk picture that varies by context.
report visual · Comparison
Methadone’s impact: clinical outcomes and retention
Evidence summarized across studies shows methadone (as part of opioid agonist therapy) improves patient retention and reduces key harms such as mortality and overdose death risk.
A randomized clinical trial found methadone treatment increased retention in opioid agonist therapy to 77% at 6 months.77%
In a large observational study, methadone treatment was associated with a 54% lower risk of overdose death compared with
54%
A Cochrane review reported that methadone maintenance therapy reduced illicit opioid use by about 50% versus placebo/no
50%
In a systematic review/meta-analysis, opioid agonist treatment (including methadone) was associated with a 47% reduction
47%
source-verifiednejm.org · jamanetwork.com · cochranelibrary.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Methadone Statistics. Gitnux. https://gitnux.org/methadone-statistics
MLA
Karl Becker. "Methadone Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/methadone-statistics.
Chicago
Karl Becker. 2026. "Methadone Statistics." Gitnux. https://gitnux.org/methadone-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)